Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc.

RCKTNYSE / NASDAQHealthcareSmall cap

$1.95-$0.16 (-7.6%)

Last close · Data as of Nov 20, 2026

Market cap
$318.8M
P/E
-1.4x
EV / EBITDA
-1.3x
Revenue
$0.00
ROCE
-76.1%

-31.3% over the last year

Rocket Pharmaceuticals, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-16.7%
3M
-44.0%
6M
-34.3%
1Y
-31.3%
5Y
Hidden
  • This period includes a one-day price step on 27 May 2025 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

Day change -$0.16 (-7.6%) from $2.11 to $1.95 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in RCKT, bought on each weekday since 2021.

News & filings

What Rocket Pharmaceuticals filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 223 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are 6.38 times current liabilities.
  • Revenue is too small for margins and growth rates to be read, so those points are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States.

Read moreShow less

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops ex vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red de Enfermedades Raras, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Sector
Healthcare
Shares outstanding
108.3M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$318.8M
P/E
-1.4x
P/B
1.2x
EV / EBITDA
-1.3x
52-week high
$5.30
52-week low
$1.95

Profitability

ROE
-80.5%
ROCE
-76.1%
ROIC
-77.8%
ROA
-67.5%

Growth

Revenue
$0.00
Net profit growth, 1Y
-13.8%
Free cash flow
-$190.5M

Solvency

Current ratio
6.38
Debt / Equity
0.09
Debt / Assets
0.08
CFO / Net profit
0.85
Cash / Market cap
24.3%

Revenue and net profit

Annual revenue, with net profit as the dashed line.

Rocket Pharmaceuticals, Inc. revenue and net profit by fiscal year
Rocket Pharmaceuticals, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$0.00-$221.9M
FY2023$0.00-$245.6M
FY2024$0.00-$258.7M
FY2025$0.00-$223.1M

Cash flows

FY2025: -$190.0M from operations, -$190.5M free after investment (dashed).

Rocket Pharmaceuticals, Inc. operating and free cash flow by fiscal year
Rocket Pharmaceuticals, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$178.1M-$186.8M
FY2023-$194.9M-$211.4M
FY2024-$209.7M-$215.6M
FY2025-$190.0M-$190.5M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$0.00
EBITDA
-$210.2M
Net profit
-$223.1M
Cash from operations
-$190.0M
Free cash flow
-$190.5M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$0.00-$210.2M-$223.1M-$190.5M-80.5%—-13.8%

Monthly returns

Month-by-month returns of RCKT across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$330.4M
Liabilities$53.2M
Equity$277.2M
Paid-in capital$1.7B
Retained earnings-$1.4B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; RCKT highlighted.

P/E against peers

RCKT has no positive P/E; the peer median is 8.6x.

Not shown (no positive earnings and no EV / Sales): Rocket Pharmaceuticals, Inc., Humacyte, Inc., Fennec Pharmaceuticals Inc., DiaMedica Therapeutics Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Rocket Pharmaceuticals, Inc.RCKTthis company$318.8M-1.4x1.2x-80.5%-1.3x
908 Devices Inc.MASS$333.5M17.1x2.3x13.6%-12.6x
Abeona Therapeutics Inc.ABEO$331.7M4.7x2.1x44.7%3.5x
Humacyte, Inc.HUMA$330.8M-8.1x106.4x-1313.4%-15.5x
Organogenesis Holdings Inc.ORGO$319.1M8.6x1.1x12.3%3.7x
Fennec Pharmaceuticals Inc.FENC$318.2M-32.7x9.0x-27.5%-37.8x
SIGA Technologies, Inc.SIGA$317.7M13.6x1.6x11.7%6.7x
DiaMedica Therapeutics Inc.DMAC$314.7M—5.6x-58.4%—
Electromed, Inc.ELMD$304.0M40.3x7.0x17.4%26.7x
Peer median—8.6x4.0x12.0%3.5x

Year-to-date ROI

RCKT since 1 January, against earlier years.

Historical volatility

RCKT's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

LineFY2025
Operating expensesOperating Expense$228.5M
Research and developmentResearch And Development$142.0M
Other operating expensesOther Operating Expenses—
Total expensesTotal Expenses$228.5M
Pretax incomePretax Income-$223.1M

Learn while you research

Academy chapters picked for Rocket Pharmaceuticals, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →